Filtered By:
Source: International Journal of Cardiology
Condition: Atrial Fibrillation
This page shows you your search results in order of relevance. This is page number 19.
Order by Relevance | Date
Total 388 results found since Jan 2013.
Comparison of linear versus cubic assessment of left atrial size in the prediction of atrial fibrillation development in hypertrophic cardiomyopathy
Left atrial (LA) enlargement evaluated by echocardiography is a very strong predictor of cardiovascular (CV) outcomes such as atrial fibrillation (AF), stroke, congestive heart failure, and CV death in multiple clinical settings [1,2]. As a consequence, researchers have focused their attention on the best method to assess LA size. Left atrium is a thin-walled cardiac chamber directly exposed to left ventricular (LV) pressure during diastole, which represents its afterload. In particular, in hypertrophic cardiomyopathy (HCM), almost all patients have some degree of LV diastolic dysfunction.
Source: International Journal of Cardiology - March 16, 2016 Category: Cardiology Authors: Alessandra Giamundo, Grazia Canciello, Antonio Rapacciuolo, Francesca Musella, Gianluigi Savarese, Teresa Strisciuglio, Eugenio Stabile, Raffaele Izzo, Bruno Trimarco, Maria Angela Losi Source Type: research
Medication adherence to rivaroxaban and dabigatran for stroke prevention in patients with non-valvular atrial fibrillation in the United States
The objective of this real-life study was to compare medication adherence to newly-initiated rivaroxaban or dabigatran therapy among NVAF patients in the United States (US).
Source: International Journal of Cardiology - March 17, 2016 Category: Cardiology Authors: Craig I. Coleman, Muralikrishna Tangirala, Thomas Evers Tags: Correspondence Source Type: research
Another side effect of ticagrelor: Atrial fibrillation
Ticagrelor, a novel direct and reversible P2Y12 receptor antagonist, was superior to clopidogrel in reducing cardiovascular events among patients with acute coronary syndrome (ACS) as demonstrated in the PLATO trial [1]. In addition, the recent PEGASUS-TIMI 54 trial also suggested that ticagrelor significantly decreased the risk of cardiovascular death, myocardial infarction or stroke in patients with prior myocardial infarction during a 33-month follow-up [2]. However, several adverse effects have been observed during the treatment with ticagrelor, such as bradyarrhythmias including sinus node pause and atrioventricular b...
Source: International Journal of Cardiology - March 21, 2016 Category: Cardiology Authors: Nixiao Zhang, Kang-Yin Chen, Jianping Zhao, Gang Xu, Guangping Li, Tong Liu Tags: Correspondence Source Type: research
Defensive medicine due to different fears by patients and physicians in geriatric atrial fibrillation patients and second victim syndrome
The treatment of atrial fibrillation (AF) patients has altered dramatically in recent years with the emergence and approval of the novel oral anticoagulants, antiplatelet or devices [1–4]; but under-treatment and under-education of AF patients continue [5] despite their high risk of stroke and clear indication for anticoagulation according to established risk scores [6,7]. Appropriate use and continued adherence are absolutely critical concerns. In a 1-year study of elderly patients with AF, 26% of patients 80years and older stopped taking oral anticoagulant drug within the first year, largely due to perceived safety issues.
Source: International Journal of Cardiology - March 22, 2016 Category: Cardiology Authors: Ozcan Ozeke, Sevgi Aras, Kazim Baser, Fatih Sen, Ozgur Kirbas, Serkan Cay, Firat Ozcan, Serkan Topaloglu, Dursun Aras, Sinan Aydogdu Source Type: research
Dabigatran-induced esophagitis: A frequently overlooked adverse effect
Atrial fibrillation (AF) is known to increase the risk of ischemic stroke and other thromboembolic events in patients with atrial fibrillation. For a long time, warfarin was the only available oral anticoagulant. Conventionally it was considered effective and widely prescribed for the prevention of thromboembolic events in patients with AF. However, routine laboratory monitoring on international normalized ratio (INR) and inevitable dose adjustments, potential interactions with several drugs and food presented significant inconvenience and challenge in managing patients taking warfarin on daily medical practice [1].
Source: International Journal of Cardiology - March 23, 2016 Category: Cardiology Authors: Nixiao Zhang, Xiushi Suzy Liu, Guangping Li, Tong Liu Tags: Correspondence Source Type: research
Cystatin C and risk of atrial fibrillation in elderly hypertensive patients without chronic kidney disease
Atrial fibrillation (AF) is the most common sustained arrhythmia in clinical practice, associated with increased risk of stroke, heart failure, and mortality [1]. Epidemiological evidence indicates that there is increased risk of AF in patients with chronic kidney disease (CKD) [2–4], while CKD is an independent risk factor for the development of AF [5–7]. Cystatin C (Cys-C) is a low molecular weight protein secreted by all nucleated cells at a constant rate. Cys-C can be freely filtrated through the glomerulus, and is almost completely reabsorbed and degraded in the proximal tubules [8].
Source: International Journal of Cardiology - March 23, 2016 Category: Cardiology Authors: Wenqian Wang, Ruyu Yuan, Panagiotis Korantzopoulos, Gang Xu, Xudan Cui, Guangping Li, Tong Liu Source Type: research
Letter: Conflicting and unresolved issue of the prognostic value of atrial fibrillation for chronic heart failure patients — Response
We would like to thank Bosseau and Donal for their interest in our paper, and agree with them about the increasing clinical importance of patients with concomitant atrial fibrillation (AF) and heart failure, regardless of ejection fraction [1]. Indeed, our analysis confirms poor prognosis in patients suffering from AF and heart failure with preserved ejection fraction (HFpEF) and heart failure with reduced ejection fraction (HFrEF). Although we identified higher crude rates of all-cause mortality with AF-HFrEF, incident stroke and heart failure admissions were similar to AF-HFpEF [2].
Source: International Journal of Cardiology - March 24, 2016 Category: Cardiology Authors: Dipak Kotecha Tags: Correspondence Source Type: research
Atrial fibrillation patients with CHA2DS2-VASc >1 benefit from oral anticoagulation prior to cardioversion
Electrical cardioversion of atrial fibrillation is associated with an increased risk of embolic stroke, but is generally considered safe if performed within 48h after onset. Our objective was to investigate if thromboembolism and bleeding in association with cardioversion of atrial fibrillation differed between patients with and without oral anticoagulation.
Source: International Journal of Cardiology - April 10, 2016 Category: Cardiology Authors: Sara Själander, Peter J. Svensson, Leif Friberg Source Type: research
Obesity and postoperative atrial fibrillation in patients undergoing cardiac surgery: Systematic review and meta-analysis
Post-operative atrial fibrillation (POAF) is one of the most common complications following cardiac surgery. However, it is unclear whether there is a relationship between obesity and POAF. We thus assessed all available evidence investigating the association between obesity and POAF, also considering any link between POAF and other post-operative conditions such as mortality, stroke, myocardial infarctions and respiratory complications.
Source: International Journal of Cardiology - May 3, 2016 Category: Cardiology Authors: Kevin Phan, Jacqueline Nguyen Khuong, Joshua Xu, Aran Kanagaratnam, Tristan D. Yan Source Type: research
Review Article: Prospective Randomized Evaluation of the Watchman Left Atrial Appendage Closure Device in Patients With Atrial Fibrillation Versus Long-Term Warfarin Therapy
Assessing the safety and effectiveness of left atrial appendage (LAA) (pouch found in the upper chambers of the heart) occlusion, using the Watchman device compared to long term warfarin therapy (drug that reduces clot formation), in preventing the risk of stroke in patients with atrial fibrillation (most common type of irregular heart beat). 90% of strokes in atrial fibrillation arise from clots forming in this pouch. By mechanically blocking it using the device less clots are suggested to be formed.
Source: International Journal of Cardiology - June 13, 2016 Category: Cardiology Authors: Djouhar Roufeida Belgaid, Zara Khan, Mariam Zaidi, Adrian Hobbs Source Type: research
Prospective randomized evaluation of the watchman left atrial appendage closure device in patients with atrial fibrillation versus long-term warfarin therapy
Assessing the safety and effectiveness of left atrial appendage (LAA) (pouch found in the upper chambers of the heart) occlusion, using the Watchman device compared to long term warfarin therapy (drug that reduces clot formation), in preventing the risk of stroke in patients with atrial fibrillation (most common type of irregular heart beat). 90% of strokes in atrial fibrillation arise from clots forming in this pouch. By mechanically blocking it using the device less clots are suggested to be formed.
Source: International Journal of Cardiology - June 13, 2016 Category: Cardiology Authors: Djouhar Roufeida Belgaid, Zara Khan, Mariam Zaidi, Adrian Hobbs Tags: Review Source Type: research
Acute ischemic stroke mimicking acute coronary syndrome
An 87year-old female patient with a history of hypertension, atrial fibrillation, and stent insertion at the left anterior descending coronary artery in 2015 presented with chief complaint of chest pain that started one day prior to admission. Along with the chest pain, the patient also complained of dizziness and vomiting. Blood pressure at admission was 140/80mmHg and heart rate 84 beats per minute. Body temperature was 36.8°C. Routine laboratory studies showed increased level of troponin I (1.084ng/mL; reference value, 0–0.78ng/mL) but normal level of creatinine kinase myocardial band (CK-MB 3.61ng/mL; reference value, 0–5ng/mL).
Source: International Journal of Cardiology - June 22, 2016 Category: Cardiology Authors: Jun Soo Lee, Pyung Chun Oh, Kwang Kon Koh Source Type: research
Mortality after stroke in patients with paroxysmal and chronic atrial fibrillation – The FibStroke Study
Recent studies have reported that patients with paroxysmal atrial fibrillation (AF) have lower risk of thromboembolism and better prognosis than patients with chronic AF. We sought to address the differences in ischaemic events in patients with paroxysmal and chronic AF.
Source: International Journal of Cardiology - June 22, 2016 Category: Cardiology Authors: Antti Palomäki, Tuomas Kiviniemi, Pirjo Mustonen, Casey Odei, Juha E.K. Hartikainen, Ilpo Nuotio, Antti Ylitalo, Päivi Hartikainen, Fausto Biancari, K.E. Juhani Airaksinen Source Type: research
Cost-effectiveness Modelling of Novel Oral Anticoagulants Incorporating Real-world Elderly Patients with Atrial Fibrillation
Novel oral anticoagulants (NOACs) expand the treatment options for patients with atrial fibrillation (AF). Their benefits need to be weighed against the risk-benefit ratio in real-world elderly patients, prompting this cost-effectiveness study of NOACs (apixaban, dabigatran, edoxaban and rivaroxaban), warfarin and aspirin for stroke prevention in AF.
Source: International Journal of Cardiology - June 22, 2016 Category: Cardiology Authors: Ying Jiao Zhao, Liang Lin, Hui Jun Zhou, Keng Teng Tan, Aik Phon Chew, Chee Guan Foo, Chia Theng Daniel Oh, Boon Peng Lim, Wee Shiong Lim Source Type: research
Dabigatran in clinical practice: Contemporary overview of the evidence
Oral anticoagulation is the cornerstone of stroke prevention in non-valvular atrial fibrillation (AF) and management of venous thromboembolism (VTE), resulting in a reduction in thrombotic complications and mortality. Benefit of vitamin K antagonists (VKAs) in such patients has been unambiguously confirmed, but VKA use is complicated by need for regular monitoring of the international normalized ratio and multiple drug and food interactions.Dabigatran is an oral direct thrombin inhibitor that can be used with fixed doses, without the need for routine anticoagulation laboratory monitoring and the advantage of few drug or diet interactions.
Source: International Journal of Cardiology - June 22, 2016 Category: Cardiology Authors: Walter Ageno, John Eikelboom, Gregory Y.H. Lip Source Type: research
